Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study

por Landy, Stephen, Munjal, Sagar, Brand-Schieber, Elimor, Rapoport, Alan M.
Publicado 2018

Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study

por Landy, Stephen, Munjal, Sagar, Brand-Schieber, Elimor, Rapoport, Alan M.
Publicado 2018

DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disab...

por Lipton, Richard B., Munjal, Sagar, Brand-Schieber, Elimor, Rapoport, Alan M.
Publicado 2019

Subcutaneous sumatriptan delivery devices: comparative ease of use and preference among migraineurs

por Andre, Anthony D, Brand-Schieber, Elimor, Ramirez, Margarita, Munjal, Sagar, Kumar, Rajesh
Publicado 2017

Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients

por Brand-Schieber, Elimor, Munjal, Sagar, Kumar, Rajesh, Andre, Anthony D, Valladao, Will, Ramirez, Margarita
Publicado 2016

Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans

por Chen, Laishun, Greenberg, William M, Brand-Schieber, Elimor, Wangsa, Julie, Periclou, Antonia, Ghahramani, Parviz
Publicado 2015

Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating atta...

por Cady, Roger K., Munjal, Sagar, Cady, Ryan J., Manley, Heather R., Brand-Schieber, Elimor
Publicado 2017

Efficacy, Tolerability, and Safety of DFN‐15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Study...

por Lipton, Richard B., Munjal, Sagar, Brand‐Schieber, Elimor, Tepper, Stewart J., Dodick, David W.
Publicado 2019

A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of epis...

por Munjal, Sagar, Brand-Schieber, Elimor, Allenby, Kent, Spierings, Egilius L.H., Cady, Roger K., Rapoport, Alan M.
Publicado 2017

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

por Farlow, Martin, Veloso, Felix, Moline, Margaret, Yardley, Jane, Brand-Schieber, Elimor, Bibbiani, Francesco, Zou, Heng, Hsu, Timothy, Satlin, Andrew
Publicado 2011